Checkpoint Inhibitor–Associated Sarcoid Reactions
How are sarcoid reactions associated with immune checkpoint inhibitors identified and characterized over time?
Following the case reports and reviews shows how this treatment-associated reaction is being described and what evidence clinicians have to assess it. New clinical and tissue findings could clarify the pattern beyond individual reports.
Where it stands now
Main bottleneck
The bounded evidence consists of reviews and case reports, including a planned report; it does not establish how consistently these reactions can be distinguished from other cancer-related findings or how they should be managed.
Watch next
A published, clinically detailed report or case series that adds verifiable tissue findings and clinical course, with further cases needed to show whether the pattern is reproducible.
Progress timeline
How the evidence has changed over time.
2025 · 1 update
- Skin lesions were inflammation while a pelvic mass was cancerPartly supportedResearch note 3 of 3 · Source date 2025-03-03
Since the previous research note · Partly supported
Track continuity
Since the previous research note: What 80 reported cases reveal about confusing inflammation with cancer progression
Previous expectation: Better ways to distinguish sarcoid inflammation from cancer progression could help teams make treatment decisions.
What this study adds: A 2025 case report documents skin biopsies showing granulomas, a separate pelvic mass showing metastatic cancer, and continued avelumab after a surgery-related pause. Immune-cell mapping adds a tissue comparison but does not validate a general diagnostic method.
Current research note
2021 · 2 updates
- What 80 reported cases reveal about confusing inflammation with cancer progressionPartly supportedResearch note 1 of 3 · Source date 2021-01-01
Since the previous research note · Partly supported
Track continuity
Since the previous research note: What did a biopsy reveal about this patient’s skin changes?
Previous expectation: Better recognition of sarcoid-like skin reactions might help clinicians manage them while considering whether cancer treatment should continue.
What this study adds: This review brings together 80 clinically evident cases and describes resemblance to cancer progression alongside separate steroid-use and treatment-discontinuation totals. It broadens the clinical dilemma beyond the earlier case without testing whether recognition improves decisions.
Current research note
- What did a biopsy reveal about this patient’s skin changes?Research note 2 of 3 · Source date 2021-01-01
How this Track works
This page changes as new evidence arrives. Open any update to see what researchers found at that point in the story.